MétaCan
Menu
Back to cohort
Record W7108609160 · doi:10.1182/blood-2025-4483

Real-world survival, cognitive and health-related quality of life outcomes of methotrexate/ifosfamide plus whole brain radiotherapy for newly diagnosed primary central nervous system lymphoma

2025· article· en· W7108609160 on OpenAlexaboutno aff

Bibliographic record

VenueBlood · 2025
Typearticle
Languageen
FieldMedicine
TopicCNS Lymphoma Diagnosis and Treatment
Canadian institutionsnot available
Fundersnot available
KeywordsPrimary central nervous system lymphomaNeurocognitiveQuality of life (healthcare)Radiation therapyLymphomaPerformance statusWisconsin Card Sorting TestChemotherapy regimen

Abstract

fetched live from OpenAlex

Abstract Background: Outcomes for primary central nervous system lymphoma (PCNSL) have been improved with high-dose methotrexate (HD-MTX)/Thiotepa-based chemotherapy followed by autologous stem cell transplantation. In limited-resource settings, HD-MTX/Ifosfamide plus whole-brain radiotherapy (WBRT) has become the local standard of care. Objectives: This study investigated the real-world effectiveness, neurocognitive functions, and health-related quality of life (HRQoL) of HD-MTX/Ifosfamide in newly diagnosed PCNSL patients. Design: A single center retrospective and prospective study. Methods: Newly diagnosed PCNSL patients treated with HD-MTX (± Ifosfamide) between 2011 and 2024 were analyzed for treatment effectiveness. For neurocognitive function and HRQoL assessments, the age- and education-matched PCNSL and non-CNS lymphoma patients in first remission were evaluated using standardized cognitive tests (Montreal Cognitive Assessment, digit span test, symbol search test and Wisconsin card sorting test-short form) and the European Organization for Research and Treatment of Cancer QLQ-C30/BN20 questionnaires. Results: Among 94 PCNSL patients enrolled in our study, 56 patients received HD-MTX/Ifosfamide (median age 56 years; 68% ECOG 0-1) and 38 patients received HD-MTX monotherapy (median age 66 years; 63% ECOG ≥2). HD-MTX/Ifosfamide demonstrated a significantly longer event-free survival (39 vs. 8 months, p=0.021) than HD-MTX monotherapy. Poor performance status (ECOG ≥2) was associated with inferior response (54.8% vs. 78.8%, p=0.013) and overall survival (Hazard ratio 2.4 [95% Confidence interval 1.57-4.56], p=0.007). Patients who received WBRT consolidation had a significantly superior 2-year progression-free survival (74.5% vs. 35.6%, p<0.001). Comparing neurocognitive tests in 20 PCNSL and 20 non-CNS lymphoma survivors in remission showed no significant difference in overall scores, but trends toward lower attention and executive function scores in the PCNSL group. Most (16/20) PCNSL survivors received WBRT. Compared to non-CNS lymphoma patients, PCNSL patients reported significantly lower HRQoL, particularly in physical functioning, which might be attributed to residual neurological deficits. Conclusion: This study supports HD-MTX/Ifosfamide as an effective, well-tolerated regimen for younger, fit PCNSL patients. WBRT remains a valuable consolidation therapy to prevent recurrence without a pronounced decline in cognitive function compared with other lymphoma survivors. However, PCNSL survivors may experience subtle declines in attention, executive function, and HRQoL.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.037
GPT teacher head0.336
Teacher spread0.299 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBloodSame topicCNS Lymphoma Diagnosis and TreatmentFrench-language works237,207